Disruption of IRE1α Through Its Kinase Domain Attenuates Multiple Myeloma
Jonathan M. Harnoss,Adrien Le Thomas,Anna Shemorry,Scot A. Marsters,David A. Lawrence,Min Lu,Yung-Chia Ariel Chen,Jing Qing,Klara Totpal,David Kan,Ehud Segal,Mark Merchant,Mike Reichelt,Heidi Ackerly Wallweber,Weiru Wang,Kevin Clark,Susan Kaufman,Maureen H. Beresini,Steven T. Laing,Wendy Sandoval,Maria Lorenzo,Jiansheng Wu,Justin Lyh,Tom De Bruyn,Amy Heidersbach,Benjamin Haley,Alvin Gogineni,Robby M. Weimer,Dong Lee,Marie-Gabrielle Braun,Joachim Rudolph,Michael J. VanWyngarden,Daniel W. Sherbenou,Patricia Gomez-Bougie,Martine Amiot,Diego Acosta-Alvear,Peter Walter,Avi Ashkenazi
DOI: https://doi.org/10.1073/pnas.1906999116
IF: 11.1
2019-01-01
Proceedings of the National Academy of Sciences
Abstract:Multiple myeloma (MM) arises from malignant immunoglobulin-secreting plasma cells and remains an incurable, often lethal disease despite recent therapeutic advances. The unfolded-protein response sensor IRE1α supports protein secretion by deploying a kinase-endoribonuclease module to activate the transcription factor XBP1s. MM cells may coopt the IRE1α-XBP1s pathway; however, the validity of IRE1α as a potential MM therapeutic target is controversial. Here we show that genetic disruption of IRE1α or XBP1s, or pharmacologic IRE1α kinase inhibition, attenuated subcutaneous or orthometastatic growth of MM tumors in mice, and augmented efficacy of two well-established frontline antimyeloma agents, bortezomib or lenalidomide. Mechanistically, IRE1α perturbation inhibited expression of key components of the ER-associated degradation machinery, as well as cytokines and chemokines known to promote MM growth. Selective IRE1α kinase inhibition reduced viability of CD138+ plasma cells while sparing CD138− cells from bone marrow of newly diagnosed MM patients or patients whose disease relapsed after 1 - 4 lines of treatment in both US- and EU-based cohorts. IRE1α inhibition preserved survival and glucose-induced insulin secretion by pancreatic microislets. Together, these results establish a strong therapeutic rationale for targeting IRE1α with kinase-based small-molecule inhibitors in MM.Significance statement Multiple myeloma (MM) is a lethal malignancy of plasma cells. MM cells have an expanded endoplasmic reticulum (ER) that is constantly under stress due to immunoglobulin hyperproduction. The ER-resident sensor IRE1α mitigates ER stress by expanding the ER’s protein-folding capacity while supporting proteasomal degradation of misfolded ER proteins. IRE1α elaborates these functions by deploying its cytoplasmic kinase-RNase module to activate the transcription factor XBP1s. The validity of IRE1α as a potential therapeutic target in MM has been questioned. Using genetic and pharmacologic disruption in vitro and in vivo, we demonstrate that the IRE1α-XBP1s pathway plays a critical role in MM growth. We further show that IRE1α’s kinase domain is an effective and safe potential small-molecule target for MM therapy.